Gregory Norden - Zoetis Independent Director

ZTS -- USA Stock  

USD 124.27  1.03  0.84%

  Director
Mr. Gregory Norden is Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough antiinfective products NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products Royalty Pharma, a leader in the acquisition of revenueproducing intellectual property and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015 Lumara Health, where he served until 2014 and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services
Age: 60  Director Since 2013      
973-822-7000  http://www.zoetis.com
Norden?s background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board.

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Omkar GoswamiDr Reddys Laboratories Ltd
2000
Allan ObermanDr Reddys Laboratories Ltd
2019
Theodore SamuelstoPerrigo Company plc
2017
Shlomo YanaiPerrigo Company plc
N/A
Adriana KaraboutisPerrigo Company plc
2017
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
J MoreauDr Reddys Laboratories Ltd
2007
Donal OConnorPerrigo Company plc
2014
Shikha SharmaDr Reddys Laboratories Ltd
2019
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Anthony ColesRegeneron Pharmaceuticals
2017
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Theodore SamuelsPerrigo Company plc
2017
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Fei WangOrigin Agritech Limited
2019
Geoffrey ParkerPerrigo Company plc
2016
Jeffrey SmithPerrigo Company plc
2017
Larry CordellOrigin Agritech Limited
2012

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
See also Your Current Watchlist. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.
Search macroaxis.com